...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial
Reply New Message
Prev Message Back To Forum Threaded View Next Message

tada, I can only go by DM past behavior on Resverlogix. I bet that ZEN-3694 will be licensed out the same way as he done with Apabetalone. First being China. (IMO)

I believe the Zenith PP was for $10Mil, not $25 Mil. And there are 2 filing noted of SEDAR in this regard. One for $3,985,000 and one for $5.7000,000 (all CAN funds).

 

Koo

Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply